PanCareLIFE - PanCare Studies in Fertility and Ototoxicity to Improve Quality of Life after Cancer during Childhood, Adolescence and Young Adulthood

Goal: PanCareLIFE is an EU-funded project (Grant No. 602030) investigating late effects of childhood cancer treatment that impact fertility and hearing impairment (ototoxicity) and health-related quality of life.

Date: 1 November 2013 - 31 October 2018

0 new
0 new
0 new
2 new

Project log

Kylie O'Brien
added a research item
Background Improved risk stratification, more effective therapy and better supportive care have resulted in survival rates after childhood cancer of around 80% in developed countries. Treatment however can be harsh, and three in every four childhood cancer survivors (CCS) develop at least one late effect, such as gonadal impairment. Gonadal impairment can cause involuntary childlessness, with serious consequences for the well-being of CCS. In addition, early menopause increases the risk of comorbidities such as cardiovascular disease and osteoporosis. Inter-individual variability in susceptibility to therapy related gonadal impairment suggests a role for genetic variation. Currently, only one candidate gene study investigated genetic determinants in relation to gonadal impairment in female CCS; it yielded one single nucleotide polymorphism (SNP) that was previously linked with the predicted age at menopause in the general population of women, now associated with gonadal impairment in CCS. Additionally, one genome wide association study (GWAS) evaluated an association with premature menopause, but no GWAS has been performed using endocrine measurements for gonadal impairment as the primary outcome in CCS. Methods As part of the PanCareLIFE study, the genetic variability of chemotherapy induced gonadal impairment among CCS will be addressed. Gonadal impairment will be determined by anti-Müllerian hormone (AMH) levels or alternatively by fertility and reproductive medical history retrieved by questionnaire. Clinical and genetic data from 837 non-brain or non-bilateral gonadal irradiated long-term CCS will result in the largest clinical European cohort assembled for this late-effect study to date. A candidate gene study will examine SNPs that have already been associated with age at natural menopause and DNA maintenance in the general population. In addition, a GWAS will be performed to identify novel allelic variants. The results will be validated in an independent CCS cohort. Discussion This international collaboration aims to enhance knowledge of genetic variation which may be included in risk prediction models for gonadal impairment in CCS.
Kylie O'Brien
added an update
The European Journal of Cancer has published our article PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity, and health related quality of life after cancer occurring among children and adolescents (103: 227 - 237 (2018)).
Danielle Nicholson
added an update
Our project Pancarelife ( is holding a final conference. Please help us spread the word.
Free, Final Pancarelife Conference 26 October 2018, Paris |
What we've learned with a focus on fertility, hearing impairment and quality of life for survivors of childhood cancer. Welcome survivors, parents, policymakers, oncologists, physicians, researchers. Learn more:
Kylie O'Brien
added an update
It’s hard to believe it’s been over 10 years since the first Erice statement in 2016, which laid out 10 key points summarising the essential components of cure and care for childhood cancer survivors!
In Nov 2016, 65 pediatric cancer experts from 17 European countries and North America, including many members of the PanCareLIFE team, met in Erice as part of the semi-annual PanCare meeting to review the original statement.
They have now published an updated version of the statement in the Journal of Cancer Survivorship:
Kylie O'Brien
added an update
The PanCareLIFE final conference will be held 26 October 2018 in Paris – save the date!
To join us, contact
Kylie O'Brien
added a project goal
PanCareLIFE is an EU-funded project (Grant No. 602030) investigating late effects of childhood cancer treatment that impact fertility and hearing impairment (ototoxicity) and health-related quality of life.